Skip to content

Clinical trials

Recruiting Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Status: Recruiting Country / region: United States Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20051
20111
20132
20141
20185
20202
20214
20223
20234
202410
20255
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting43

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center7
Fred Hutchinson Cancer Center3
Novartis Pharmaceuticals3
Ascentage Pharma Group Inc.2
Center for International Blood and Marrow Transplant Research2
Masonic Cancer Center, University of Minnesota2
Alliance for Clinical Trials in Oncology1
Cancer Support Community, Research and Training Institute, Philadelphia1
Children's Hospital Medical Center, Cincinnati1
City of Hope Medical Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive43
Leukemia, Myeloid, Acute23
Precursor Cell Lymphoblastic Leukemia-Lymphoma20
Myelodysplastic Syndromes17
Leukemia, Lymphocytic, Chronic, B-Cell10
Lymphoma, Non-Hodgkin9
Myeloproliferative Disorders9
Hodgkin Disease8
Primary Myelofibrosis8
Leukemia, Myelomonocytic, Chronic7

Trials

Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.